Please amend page 20, line 1 as follows:

~~Claims~~ **What is claimed is:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A peptide of the amino acid sequence of formula (I)

$Z^1$-$X^1$-$X^2$-$X^3$-$X^4$-$X^5$-Gly-$X^7$-$X^8$-$X^9$- $Z^2$-$Y^1$ (I)

or formula (II)

$Z^1$-$X^1$-Tyr-$X^3$(-Ala or Ser)-Asp-Gly-$X^7$-(Tyr or Phe)-Asp- $Z^2$-$Y^1$ (II)

wherein

$X^1$ is an amino acid selected from the group Ser, His, Thr, Ala, Gln, Phe, Gly and Ile

$X^2$ is an amino acid selected from the group Tyr, Arg and Phe

$X^3$ is an amino acid selected from the group Tyr, Ser, Asn, Glu, Asp and Thr

$X^4$ is an amino acid selected from the group Ser, Ala, Gly, Asp and Phe

$X^5$ is an amino acid selected from the group Asp and Ser,

$X^7$ is an amino acid selected from the group Thr, Val, Met, Ser, Trp, Tyr, Leu and Ala

$X^8$ is an amino acid selected from the group Tyr,Phe and Leu

$X^9$ is an amino acid selected from the group Asp, Ser and Glu

$Z^1$ represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue, or a residue capable of forming a thioether preferably the residue is Q-C(=O) wherein Q represents $-(CH_2)n$ or $-(CH_2)_n$-$C_6H_4$ where n represents a positive integer 1 to 10 or is absent and

$Z^2$ represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue or is absent

$Y^1$ represents 1-10 amino acids or is absent

or pharmaceutically acceptable salts thereof.

2. (Original) A peptide according to claim 1 of the amino acid sequence
Cys-Ser-Tyr-Tyr-Ser-Asp-Gly-Val-Tyr-Asp-Cys, (SEQ ID NO 1),
Cys-His-Tyr-Ser-Ser-Asp-Gly-Thr-Tyr-Asp-Cys, (SEQ ID NO 2),
Cys-Thr-Tyr-Asn-Gly-Asp-Gly-Ser-Phe-Asp-Cys, (SEQ ID NO 3),
Cys-Ala-Tyr-Glu-Ala-Asp-Gly-Trp-Phe-Asp-Cys, (SEQ ID NO 4),
Cys-Ser-Tyr-Ser-Ala-Asp-Gly-Thr-Leu-Asp-Cys, (SEQ ID NO 5),
Cys-Gln-Tyr-Asp-Ser-Ser-Gly-Met-Tyr-Asp-Cys, (SEQ ID NO 6),
Cys-Phe-Phe-Asp-Ser-Ser-Gly-Tyr-Phe-Asp-Cys, (SEQ ID NO 7),
Cys-Thr-Tyr-Ser-Ala-Asp-Gly-Leu-Tyr-Asp-Cys, (SEQ ID NO 8),
Cys-His-Phe-Asp-Gly-Asp-Gly-Ser-Tyr-Asp-Cys, (SEQ ID NO 9),
Cys-Thr-Tyr-Glu-Pro-Ser-Gly-Met-Tyr-Asp-Cys, (SEQ ID NO 10),
Cys-Gln-Tyr-Thr-Ala-Asp-Gly-Ala-Phe-Asp-Cys, (SEQ ID NO 11),
Cys-Ile-Tyr-Glu-Ser-Asp-Gly-Met-Phe-Ser-Cys, (SEQ ID NO 12),
Cys-Gly-Arg-Ser-Asp-Gly-Thr-Trp-Tyr-Glu-Cys, (SEQ ID NO 13) or
Cys-Ser-Tyr-Tyr-Ala-Asp-Gly-Met-Tyr-Ser-Cys, (SEQ ID NO 14).

3. (Currently amended) A targetable diagnostic and/ or therapeutically active agent of formula (III)
V-L-Z Formula (III)
wherein the vector V is a peptide according to claim 1~~–2~~
L represents a bond, a spacer or a linker and
Z represents an antineoplastic agent, a reporter moiety or a group that optionally can carry an imaging moiety M.

4. ( Original) An agent as claimed in claim 3 where Z is a chelating agent of Formula IV



(IV)

where:

each $R^1$, $R^2$, $R^3$ and $R^4$ is independently an R group;

each R group is independently H or $C_{1\text{-}10}$ alkyl, $C_{3\text{-}10}$ alkylaryl, $C_{2\text{-}10}$ alkoxyalkyl, $C_{1\text{-}10}$ hydroxyalkyl, $C_{1\text{-}10}$ alkylamine, $C_{1\text{-}10}$ fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

5. (Currently amended) An agent as claimed in ~~any of the previous claims 3 to 4~~ claim 3 wherein Z comprises a reporter moiety, M wherein the reporter moiety M comprises metal radionuclides, paramagnetic metal ions, fluorescent metal ions, heavy metal ions or cluster ions.

6. (Original) An agent as claimed in claim 5 wherein the reporter moiety M comprises $^{90}Y$, $^{99m}Tc$, $^{111}In$, $^{47}Sc$, $^{67}Ga$, $^{51}Cr$, $^{177m}Sn$, $^{67}Cu$, $^{167}Tm$, $^{97}Ru$, $^{188}Re$, $^{177}Lu$, $^{199}Au$, $^{203}Pb$, $^{141}Ce$ or $^{18}F$.

7. (Currently amended) An agent as claimed in ~~claims 3 to 6~~ claim 3 where each reporter (Z) can carry a multiplicity of vectors V.

8. (Original) An agent as claimed in claim 3 where the antineoplastic agent Z represent cyclophosphamide, chloroambucil, busulphan, methotrexate, cytarabine, fluorouracil, vinblastine, paclitaxel, doxorubicin, daunorubicin, etoposide, teniposide, cisplatin, amsacrine or docetaxel.

9. (original) A pharmaceutical composition comprising an effective amount of a compound of general Formula (III) or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents for use in enhancing image contrast in *in vivo* imaging or for treatment of a disease.

10. (Currently amended) A method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a compound as claimed in ~~claims 3 to 7~~ claim 3, which method comprises generating an image of at least part of said body.